- Phase 2 trial with lead neuroprotective molecule OCS-05 (formerly ACT-01) completed by licensing partner Oculis met primary safety endpoint and key secondary efficacy endpoints with no serious adverse events
- Trial success clearly supports Accure’s translational approach to drug development and partnership business model
- Accure has two other assets in the pipeline to treat range of central nervous system (CNS) disorders
You can read the whole new here: